Advertisement

Topics

FDA green lights first non-opioid therapy to manage symptoms of opioid withdrawal

05:16 EDT 17 May 2018 | Pharmafile

As the opioid epidemic continues to grip the US as the leading cause of deaths in those under the age of 50, the FDA has made an important leap with the approval of Lucemyra (lofexidine hydrochloride) for managing the symptoms of opioid withdrawal in adult patients - the first non-opioid therapy for this purpose.

read more

Original Article: FDA green lights first non-opioid therapy to manage symptoms of opioid withdrawal

NEXT ARTICLE

More From BioPortfolio on "FDA green lights first non-opioid therapy to manage symptoms of opioid withdrawal"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...